Oracle and Ci4CC join forces to advance AI in cancer research
The partnership will focus on personalised medicine, clinical trials, and data integration.
Oracle Health and Life Sciences has announced a strategic collaboration with the Cancer Center Informatics Society (Ci4CC) to accelerate AI innovation in oncology. The partnership unites Oracle’s healthcare technology with Ci4CC’s national network of cancer research institutions.
The two organisations plan to co-develop an electronic health record system tailored to oncology, integrating clinical and genomic data for more effective personalised medicine. They also aim to explore AI-driven drug development to enhance research and patient outcomes.
Oracle executives said the collaboration represents an opportunity to use advanced AI applications to transform cancer research. The Ci4CC President highlighted the importance of collective innovation, noting that progress in oncology relies on shared data and cross-institution collaboration.
The agreement, announced at Ci4CC’s annual symposium in Miami Beach US, remains non-binding but signals growing momentum in AI-driven precision medicine. Both organisations see the initiative as a step towards turning medical data into actionable insights that could redefine oncology care.
Would you like to learn more about AI, tech and digital diplomacy? If so, ask our Diplo chatbot!
